NEWS

Recent research and activities at Ragon

New Findings Show Strikingly Early Seeding of HIV Viral Reservoir

The most critical barrier for curing HIV-1 infection is the presence of the viral reservoir, the cells in which the HIV virus can lie dormant for many years and avoid elimination by antiretroviral drugs. Very little has been known about when and where the viral reservoir is established during acute HIV-1 infection, or the extent […]

Read more
Employee Highlight: Oluwaseun Ogunbodede

The expressed goal of the Ragon Insitute is lofty: to harness the immune system to prevent and cure human disease. But behind every principal investigator publishing a new finding is a team of support staff enabling their research. In the offices, administrative assistants, regulatory staff, and grant administrators manage the office, monitor funding, and ensure […]

Read more
Makadzange Opens New Lab in Zimbabwe

A new Ragon Institute-associated lab has been recently opened at the University of Zimbabwe in Harare. The goal of the lab is to facilitate translational research in Africa by encouraging clinicians and scientists to work together to identify critical research questions based on clinical observations and identify solutions in the lab.   The laboratory was […]

Read more
Study Finds How Protein Blocks HIV Life Cycle in Elite Controllers

Investigators from Massachusetts General Hospital (MGH) and the Ragon Institute of MGH, MIT and Harvard have learned more about one way the immune systems of elite controllers – those rare individuals able to control HIV infection without drug treatment – block a key step in the virus’s life cycle. In a paper appearing in Cell […]

Read more
Kwon Recognized for Mentorship

Ragon Institute faculty member Dr. Douglas Kwon has been recognized for his mentorship by Harvard Medical School.   In the field of research, mentoring is crucial in order to encourage and support the career development of the next generation of young scientists who will build on existing scientific knowledge to achieve common goals.  Mentoring requires […]

Read more
Ragon Supports AIDS Walk 2014

Sunday, June 1 was a beautiful day for a walk… The 29th annual AIDS Walk Boston & 5K Run that is!     For the 18th year in a row, Team Ragon walked with the goal, not only of raising money, but also of raising awareness. As the 78 team members joined the thousands who […]

Read more
Employee Highlight: Dan Karel

The expressed goal of the Ragon Insitute is lofty: to harness the immune system to prevent and cure human disease.  But behind every principal investigator publishing a new finding is a team of support staff enabling their research.  In the offices, administrative assistants, regulatory staff, and grant administrators manage the office, monitor funding, and ensure […]

Read more
Newsletter Vol 11: Ragon Celebrates Five Years, New Faculty Members

On February 28, the Ragon Institute celebrated five years of innovation and collaboration at the Walker Memorial on the Massachusetts Institute of Technology campus in Cambridge. Over 200 employees, friends and collaborators of the Institute gathered that evening to celebrate the ongoing commitment to progressive scientific discovery.   Since its establishment in 2009, the Ragon […]

Read more
Recipients of the 2014 Seed Grants Announced

Five principal investigators from the US and South Africa were awarded the first round of funding from the new Ragon TB Seed Grants.   One of the primary missions of the Ragon Institute is to provide a means for rapidly funding promising studies and emerging concepts in the field of HIV research. Since 2009, the […]

Read more
Ragon Team Receives Grant to Develop Engineered Cytotoxic T-Cells

The Ragon Institute fosters an environment that breaks down silos between different fields of science. This has allowed Dr. Brad Jones, Ragon Institute post-doctoral fellow, to move forwards with an idea that takes an innovative technology developed in the laboratory of Dr. Darrell Irvine for the treatment of cancer, and to combine it with the […]

Read more
Employee Highlight: Alyssa Clark

The expressed goal of the Ragon Insitute is lofty: to harness the immune system to prevent and cure human disease.  But behind every principal investigator publishing a new finding is a team of support staff enabling their research.  In the offices, administrative assistants, regulatory staff, and grant administrators manage the office, monitor funding, and ensure […]

Read more
Scully Receives Grant to Study Gender Differences in HIV Treatment

Dr. Eileen Scully, M.D., Ph.D. of Massachusetts General Hospital and the Ragon Institute has been awarded funding from amfAR’s Research Consortium on HIV Eradication (ARCHE) program.   Founded in 1985, amfAR, one of the world’s leading nonprofit organizations, is dedicated to ending the global AIDS epidemic through innovative research. The ARCHE program was launched in […]

Read more
Ndhlovu Recognized by CAVD as Early Career Investigator

This month, Ragon Institute Instructor Zaza Ndhlovu, PhD was recognized by the Collaboration for AIDS Vaccine Discovery (CAVD) for significant contributions to research conducted within the CAVD.   The Collaboration for AIDS Vaccine Discovery (CAVD) is an international network of scientists and experts dedicated to designing a variety of novel HIV vaccine candidates and advancing […]

Read more
The Ragon Institute 2013 Annual Report

The 2013 Ragon Institute Annual Report is now available to view online or download! Learn about the Institute accomplishments during its fifth year!   2013 Ragon Institute Annual Report   [With the interactive plugin above, you can use the menu bar to share, download as a PDF, or expand to full screen.]   If you […]

Read more
Ragon Study Hones In On Mystery of HIV-Eliminating Vaccine Antibodies

NIH Grantees Sharpen Understanding of Antibodies that May Cut Risk of HIV Infection   What immune response should a vaccine elicit to prevent HIV infection? Two studies bring scientists closer to answering this question by identifying previously unrecognized attributes of antibodies that appear to have reduced the risk of HIV infection in the clinical trial […]

Read more